PD‐L1/TIGIT bispecific antibody showed survival advantage in animal model
Abstract
Dear Editor, Although PD-1 and PD-L1 (programmed cell death1/ligand 1) antibody therapies have provided persistent benefits in various cancers, their clinical applications have been limited by relatively low response rates and the occurrence of drug resistance.1 Thus, they have been extensively investigated in combination with a variety of antitumor therapies, such as inhibitors to other immune checkpoints in combinational or bispecific antibody (BsAb) therapeutical strategies, to improve the response rates or efficacies in the clinic.2 TIGIT (T-cell immunoreceptor with immunoglobulin and ITIM domains) is an inhibitory T-cell immunoreceptor discovered in 2009,3 which is expressed mainly on regulatory T cells (Tregs), memory T-cells, and NK cells. Combination therapies that block both PD-L1 and TIGIT pathways have superior clinical benefits to PD-L1 monotherapy.4 BsAbs simultaneously targeting both pathways are also entering clinical trials (NCT05102214), but whether BsAbs are superior to combinational approaches has not been elucidated yet. We reported here a novel bispecific anti-PD-L1/TIGIT antibodywith potent effects in enhancing human IL-2 production by primary human T cells in vitro and in increasing the overall survival in a transgenic mouse model in vivo.More importantly, we compared the tetravalent bispecific anti-PD-L1/TIGIT antibody to mAb and combination therapies head-to-head systematically, and our data supported the the advantage of taking bispecific approach…
How strong is the evidence?
Evidence Hub reads this as a editorial / letter, done in animal, not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Chaos and quantum thermalization
- The Dalton quantum chemistry program system
- Cord Blood Leptin and Adiponectin as Predictors of Adiposity in Children at 3 Years of Age: A Prospective Cohort Study
- Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes
- Stable adiabatic quantum batteries
- A novel self-lipid antigen targets human T cells against CD1c(+) leukemias
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.